Format

Send to

Choose Destination
Biochem Biophys Res Commun. 2019 Nov 26;520(1):225-230. doi: 10.1016/j.bbrc.2019.10.001. Epub 2019 Oct 3.

The evaluation of Cannabidiol's effect on the immunotherapy of Burkitt lymphoma.

Author information

1
Division of Blood and Bone Marrow Transplantation, Department of Medicine, University of Louisville School of Medicine, Louisville, KY, USA; Division of Haematology, National Center for Global Health and Medicine, Tokyo, Japan.
2
Dupont Manual High School, Louisville, KY, USA.
3
North Oldham High School, Goshen, KY, USA.
4
Northern Kentucky University, Highland Heights, KY, USA.
5
Division of Blood and Bone Marrow Transplantation, Department of Medicine, University of Louisville School of Medicine, Louisville, KY, USA. Electronic address: j0park27@louisville.edu.

Abstract

AIM:

AF1q has a precise oncogenic function. The purpose of this study is to investigate whether CBD has an effect on the AF1q/ICAM-1 regulatory axis in Burkitt's lymphoma (BL), and thus has potential to enhance immunotherapy and reduce side effects.

METHODS:

We established BL cell lines with altered AF1q expression using lentivirus. After confirmation of gene expression by RT-PCR, cells were treated with CBD followed by co-culture of killing assay.

RESULTS:

AF1q increased oncogenic growth and colony formation, and induced resistance against cell-mediated cytotoxic chemotherapy through attenuation of ICAM-1 expression in BL. CBD was able to reverse the acquired resistance mediated by AF1q/ICAM-1 regulatory axis.

CONCLUSION:

CBD holds potential to enhance the efficacy of immunotherapy for BL with hyperactive AF1q/ICAM-1 regulatory axis, and warrants further study.

KEYWORDS:

AF1q; BL; Burkitt lymphoma; CBD; Cannabidiol; ICAM-1; Immunotherapy

PMID:
31587870
DOI:
10.1016/j.bbrc.2019.10.001

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center